Trial Profile
The SOURCE Study: Schizophrenia Outcomes-Utilization, Relapse, and Clinical Evaluation: a prospective 2-year observational study of patients with schizophrenia who initiate treatment with injectable risperidone long-acting microspheres (RISPERDAL CONSTA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2014
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms SOURCE
- Sponsors Janssen
- 19 Aug 2008 New trial record.